Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Department of Health and Human Services
This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.
Funding
Award size
$1M – $10M
Award ceiling
1000000
Type
Grant
Dates
Deadline
Later
Posted
12/30/2024
Closes
2028-05-07
Eligibility
Eligibility
Private institutions of higher educationCity or township governmentsFor profit organizations other than small businessesState governmentsOthers (see text field entitled "Additional Information on Eligibility" for clarification)Special district governmentsCounty governmentsNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationIndependent school districtsNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationPublic and State controlled institutions of higher educationSmall businessesNative American tribal organizations (other than Federally recognized tribal governments)
Program
Funding area
Health - HL
Opportunity #
PAR-25-374
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov